Read by QxMD icon Read

psoriasis cardiovascular event

Maroula G Kokotou, Dimitris Limnios, Aikaterini Nikolaou, Anastasia Psarra, George Kokotos
The regulation of the catalytic activity of the various phospholipase A2 enzymes is of high importance because these enzymes are involved in various pathological conditions such as arthritis, cardiovascular diseases, neurological diseases, and cancer. Thus, a great effort has been devoted in developing synthetic inhibitors as new agents to treat inflammatory diseases. Some of them have reached clinical trials. Areas covered: This review article discusses the phospholipase A2 inhibitors presented in patent literature from October 2012 to June 2016, their activities in vitro and in vivo as well as the results of clinical trials using synthetic PLA2 inhibitors...
October 8, 2016: Expert Opinion on Therapeutic Patents
Jatinder Singh, Ramanpreet Shah, Dhandeep Singh
The mast cells are integral part of immune system and they have pleiotropic physiological functions in our body. Any type of abnormal stimuli causes the mast cells receptors to spur the otherwise innocuous mast cells to degranulate and release inflammatory mediators like histamine, cytokines, chemokines and prostaglandins. These mediators are involved in various diseases like allergy, asthma, mastocytosis, cardiovascular disorders, etc. Herein, we describe the receptors involved in degranulation of mast cells and are broadly divided into four categories: G-protein coupled receptors, ligand gated ion channels, immunoreceptors and pattern recognition receptors...
September 29, 2016: International Immunopharmacology
W Rungapiromnan, Z Z N Yiu, R B Warren, C E M Griffiths, D M Ashcroft
BACKGROUND: Concerns have been raised regarding an increased risk of major adverse cardiovascular events (MACEs) (myocardial infarction, cerebrovascular accident, or cardiovascular death) in patients treated with anti-interleukin (IL)-12/23 agents for moderate-to-severe psoriasis. OBJECTIVE: To examine the risk of MACEs in adult patients with plaque psoriasis that are exposed to biologic therapies via a meta-analysis of randomised controlled trials (RCTs). METHODS: (i) Data sources: Systematic searches were performed in the Cochrane Library, MEDLINE and EMBASE, US Food and Drug Administration, European Medicines Agency, individual pharmaceutical companies online search platforms and 5 trials registers (until 31 March 2016)...
August 12, 2016: British Journal of Dermatology
Jashin J Wu, Bruce E Strober, Peter R Hansen, Ole Ahlehoff, Alexander Egeberg, Abrar A Qureshi, Debbie Robertson, Hernan Valdez, Huaming Tan, Robert Wolk
BACKGROUND: Psoriasis is a systemic inflammatory condition that is associated with a higher risk of cardiovascular (CV) disease. Tofacitinib is being investigated as a treatment for psoriasis. OBJECTIVE: We sought to evaluate the effects of tofacitinib on CV risk factors and major adverse CV events (MACEs) in patients with plaque psoriasis. METHODS: Changes in select CV risk factors and the incidence rate (IR) of MACEs were evaluated in patients who were treated with tofacitinib...
November 2016: Journal of the American Academy of Dermatology
Ehrin J Armstrong, James G Krueger
Psoriasis is a chronic inflammatory disease associated with a variety of co-morbid conditions, including cardiovascular disease. Advancements in our understanding of the cellular and molecular mechanisms of psoriasis have led to a better understanding regarding its pathogenesis, which in turn has stimulated ongoing research to identify the underlying pathophysiology responsible for the increased risk of cardiovascular events associated with psoriasis. Although not yet fully elucidated, emerging evidence points to immune-mediated inflammation as a process that contributes to endothelial cell dysfunction, dyslipidemia, and atherosclerosis as key processes influencing cardiovascular disease in psoriasis...
August 15, 2016: American Journal of Cardiology
Zheng-Sheng Yang, Ning-Ning Lin, Li Li, Yang Li
TNF inhibitors have been used in psoriasis (Pso) and psoriatic arthritis (PsA), which were associated with increased risk of cardiac and cerebrovascular events. However, whether TNF inhibitors reduce cardiovascular event is still unclear. Therefore, we aimed to evaluate the effect of TNF inhibitors on adverse cardiovascular events (CVEs) in Pso with or without PsA. We undertook a meta-analysis of clinical trials identified in systematic searches of MEDLINE, EMBASE, Wanfang database, Cochrane Database, and Google scholar through December 31, 2015...
October 2016: Clinical Reviews in Allergy & Immunology
Alexander Egeberg, Louise E Bruun, Lotus Mallbris, Gunnar H Gislason, Lone Skov, Jashin J Wu, Peter R Hansen
BACKGROUND: Patients with psoriasis may have increased risk of major adverse cardiovascular (CV) events (MACE), and a family history of CV disease (CVD) is an independent risk factor for MACE. OBJECTIVE: We investigated the risk of first-time MACE in patients with psoriasis with or without a family history of CVD. METHODS: Between January 1, 1997, and December 31, 2011, we identified 2,722,375 individuals, including 25,774 and 4504 patients with mild and severe psoriasis, through administrative registers...
August 2016: Journal of the American Academy of Dermatology
Kaitlyn M Yim, April W Armstrong
Psoriasis and psoriatic arthritis are associated with a significantly increased risk of cardiovascular risk factors and major adverse cardiovascular events (MACE). Active research is ongoing to elucidate this relationship between psoriatic diseases and cardiovascular comorbidities, as well as their shared pathogenic mechanisms. This review focuses on (1) the epidemiologic association between psoriasis and cardiovascular risk factors, (2) the epidemiologic association between psoriasis and MACE, (3) the epidemiologic association between psoriatic arthritis, cardiovascular risk factors, and MACE, and (4) proposed mechanisms for the contribution of psoriatic diseases to cardiovascular diseases...
May 24, 2016: Rheumatology International
Wayne P Gulliver, Shane Randell, Susanne Gulliver, Sean Connors, Hervé Bachelez, Don MacDonald, Neil Gladney, Andrea Morrissey, Patrick Fleming
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disorder that affects approximately 2% to 3% of the population, which translates to 17 million in North America and Europe and approximately 170 million people worldwide. Although psoriasis can occur at any age, most cases develop before age 40 years. Some larger studies have noted bimodal age at onset with the first peak occurring at approximately age 30 years and the second peak at around 55 to 60 years, but most patients have a younger age of onset (15-30 years)...
May 10, 2016: Journal of Cutaneous Medicine and Surgery
Na Fang, Menglin Jiang, Yu Fan
The association between psoriasis and carotid intima-media thickness (CIMT) or impaired flow-mediated dilation (FMD) remains controversial. We aimed to evaluate the extent of subclinical atherosclerosis as measured by CIMT and FMD in patients with psoriasis by conducting a meta-analysis.A systematic literature search was performed using PubMed, Embase, Cochrane databases, China National Knowledge Infrastructure, and VIP databases up to February 2015. Observational studies investigating CIMT or FMD in patients with psoriasis and controls were eligible...
May 2016: Medicine (Baltimore)
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, Craig L Leonardi, Andrew Blauvelt, Tsen-Fang Tsai, Yankun Gong, Jiaqing Huang, Charis Papavassilis, Todd Fox
BACKGROUND: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque psoriasis. OBJECTIVE: We reviewed safety data from the secukinumab psoriasis phase II/III program. METHODS: Data were pooled from 10 phase II/III secukinumab psoriasis studies. RESULTS: Analysis included 3993 subjects; 3430 received secukinumab, representing 2725 subject-years (SYs) of exposure...
July 2016: Journal of the American Academy of Dermatology
Ari Polachek, Zahi Touma, Melanie Anderson, Lihi Eder
OBJECTIVES: To assess the magnitude of risk of cardiovascular and cerebrovascular morbidity in patients with psoriatic arthritis (PsA) compared with the general population through a systematic review and a meta-analysis of observational studies. METHODS: We searched Medline, EMBase, and Cochrane databases as well as abstract archives from rheumatology conferences. Observational studies that met the following criteria were assessed by 2 researchers: 1) PsA diagnosis; 2) Cardiovascular or cerebrovascular outcomes; 3) Comparison group of individuals without psoriasis and rheumatic diseases; 4) case-control, cross-sectional or cohort studies...
April 25, 2016: Arthritis Care & Research
Sinan İnci, Gökhan Aksan, Pınar Doğan
Currently, coronary artery disease (CAD) is considered a major ailment in humans with widespread prevalence. CAD also accounts for high mortality rates around the world that involves several known risk factors. Chemerin is a novel adipokinine that is associated with inflammation and adipogenesis. Furthermore, experimental and clinical data indicate that localized as well as circulating chemerin expression and activation are elevated in numerous metabolic and inflammatory diseases including psoriasis, obesity, type 2 diabetes, metabolic syndrome and cardiovascular disease...
April 2016: Therapeutic Advances in Endocrinology and Metabolism
Trinitario Pina, Alfonso Corrales, Raquel Lopez-Mejias, Susana Armesto, Marcos A Gonzalez-Lopez, Ines Gómez-Acebo, Begoña Ubilla, Sara Remuzgo-Martínez, M Carmen Gonzalez-Vela, Ricardo Blanco, Jose L Hernández, Javier Llorca, Miguel A Gonzalez-Gay
The aim of the present study was to determine if the use of the anti-tumor necrosis factor (TNF)-α monoclonal antibody adalimumab could improve endothelial function and arterial stiffness in patients with moderate to severe psoriasis. This was a prospective study on a series of consecutive patients with moderate to severe psoriasis who completed 6 months of therapy with adalimumab. Patients with history of cardiovascular events, diabetes mellitus, kidney disease, hypertension or body mass index of 35 kg/m(2) or more were excluded...
April 7, 2016: Journal of Dermatology
F Bardazzi, G Odorici, F Ferrara, M Magnano, R Balestri, A Patrizi
BACKGROUND: Psoriasis is a multi-systemic disease involving the skin and joints, but it is also characterized by endothelial dysfunction, which may cause sexual impotence and erectile dysfunction (ED), an embarrassing disease frequently neglected by dermatologists. OBJECTIVE: The principal objective was assessing the relationship between the severity of psoriasis and the severity of ED. We also investigated whether severity of psoriasis was related to International Index of Erectile Function-5 (IIEF-5) score, whether genital lesions worsened the IIEF-5 score, whether ED was related to factors such as diabetes, smoking and hypertension, and finally the overall the psychological factors felt by the patient...
August 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Angelo A Izzo, Sung Hoon-Kim, Rajan Radhakrishnan, Elizabeth M Williamson
Systematic reviews and meta-analyses represent the uppermost ladders in the hierarchy of evidence. Systematic reviews/meta-analyses suggest preliminary or satisfactory clinical evidence for agnus castus (Vitex agnus castus) for premenstrual complaints, flaxseed (Linum usitatissimum) for hypertension, feverfew (Tanacetum partenium) for migraine prevention, ginger (Zingiber officinalis) for pregnancy-induced nausea, ginseng (Panax ginseng) for improving fasting glucose levels as well as phytoestrogens and St John's wort (Hypericum perforatum) for the relief of some symptoms in menopause...
May 2016: Phytotherapy Research: PTR
Alexander Egeberg, Gunnar H Gislason, Peter R Hansen
IMPORTANCE: Hidradenitis suppurativa (HS) is a common inflammatory skin disease. The disease has been associated with cardiovascular (CV) risk factors, but the risk of CV disease in patients with HS is unknown. OBJECTIVE: To investigate CV risk in patients with HS. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study was conducted from January 1, 1997, to December 31, 2011, using individual-level linkage of nationwide administrative registers...
April 2016: JAMA Dermatology
Akihiko Asahina, Takafumi Etoh, Atsuyuki Igarashi, Shinichi Imafuku, Hidehisa Saeki, Yoshiyuki Shibasaki, Yukiko Tomochika, Shigeyuki Toyoizumi, Makoto Nagaoka, Mamitaro Ohtsuki
Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis. Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double-blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 weeks, open-label 10 mg b.i.d. for 4 weeks, then variable 5 or 10 mg b.i.d. to Week 52. Primary end-points at Week 16 were the proportion of patients achieving at least a 75% reduction in Psoriasis Area and Severity Index (PASI75) and Physician's Global Assessment of "clear" or "almost clear" (PGA response) for psoriasis, and 20% or more improvement in American College of Rheumatology criteria (ACR20) for patients with psoriatic arthritis...
August 2016: Journal of Dermatology
Whan B Kim, Judy Qiang, Jensen Yeung
INTRODUCTION: Previous reports have shown inconsistent findings with regard to the relationship between biologic therapy and risk for major adverse cardiovascular events (MACEs). OBJECTIVES: The aim of this study was to determine the overall rate of MACEs in a cohort of 398 patients. METHODS: All patients treated with biologics for psoriasis at 2 academic centers in Toronto, Ontario, between September 2005 and September 2014 were considered for inclusion...
July 2016: Journal of Cutaneous Medicine and Surgery
Patricia Tejón, Isla Morante, Iván Cabezas, Cristina Sarasqueta, Pablo Coto, Rubén Queiro
OBJECTIVES: We aimed to determine which disease features could be associated to the risk of cardiovascular (CV) events in a PsA cohort from a tertiary care institution. METHODS: We conducted an age- and sex-matched case-control study in which the cases were all PsA patients who developed cardiovascular (CV) events during the study period (2010-14). The control group was free of CV events during the same period. Univariate analysis was performed to examine unadjusted associations of potential risk factors...
March 2016: Clinical and Experimental Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"